Improved Pharmacokinetic and Biodistribution Properties of the Selective Urokinase Inhibitor PAI-2 (SerpinB2) by Site-Specific PEGylation: Implications for Drug Delivery-Reference-Cited by-同舟云学术

Improved Pharmacokinetic and Biodistribution Properties of the Selective Urokinase Inhibitor PAI-2 (SerpinB2) by Site-Specific PEGylation: Implications for Drug Delivery

Published:2014-09-18 Issue:3 Volume:32 Page:1045-1054
ISSN:0724-8741
Container-title:Pharmaceutical Research
language:en
Short-container-title:Pharm Res

Author:

Vine Kara Lea,Lobov Sergei,Chandran Vineesh Indira,Harris Nathanial Lachlan Ewart,Ranson Marie

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s11095-014-1517-x.pdf

Reference40 articles.

1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72(1):1–22.

2. Lund IK, Illemann M, Thurison T, Christensen IJ, Hoyer-Hansen G. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr Drug Targets. 2011;12(12):1744–60.

3. Ranson M, Andronicos NM. Plasminogen binding and cancer: promises and pitfalls. Front Biosci. 2003;8:s294–304.

4. Stillfried GE, Saunders DN, Ranson M. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res. 2007;9(1):R14.

5. Carriero MV, Franco P, Votta G, Longanesi-Cattani I, Vento MT, Masucci MT, et al. Regulation of cell migration and invasion by specific modules of uPA: mechanistic insights and specific inhibitors. Curr Drug Targets. 2011;12(12):1761–71.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioproduced Nanoparticles Deliver Multiple Cargoes via Targeted Tumor Therapy In Vivo;ACS Omega;2024-07-23

2. Pegylated LyeTx I-b peptide is effective against carbapenem-resistant Acinetobacter baumannii in an in vivo model of pneumonia and shows reduced toxicity;International Journal of Pharmaceutics;2021-11

3. Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma;Cancers;2021-08-14

4. Treatment of Lung Cancer by Peptide-Modified Liposomal Irinotecan Endowed with Tumor Penetration and NF-κB Inhibitory Activities;Molecular Pharmaceutics;2020-08-20

5. Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy;International Journal of Nanomedicine;2018-05